Plain-English translation of NCT07216560 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is the first study of in human patients with advanced gastrointestinal cancers. Researchers want to understand how safe this new medication is, how your body processes it, and whether it can help slow or stop cancer growth in people whose cancer has not responded to standard treatments.
Current treatments for advanced digestive system cancers don't work for everyone, and some people's cancers stop responding over time. This study explores whether this medication could offer a new treatment option for people in that situation.
You likely qualify if…
You likely don't qualify if…
You would receive the medication (likely as an injection or infusion) as part of your cancer treatment plan. The study involves regular clinic visits where your doctors will monitor your health with blood tests, imaging scans, and physical exams to track how well the medication is working and what side effects you experience. The exact schedule and duration would be discussed with the research team, but participants are generally monitored closely throughout the trial.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States